Clinical Trials Browser

Phase 3 × Completed × Ipilimumab × Clear all

NCT02231749 2026-05-27

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase 3 Completed

1,096 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT03143153 2026-02-17

CheckMate 648

Phase 3 Completed

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT04334759 2026-01-22

DREAM3R

Phase 3 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT03469960 2025-11-18

DICIPLE

Phase 3 Completed

Non-Small Cell Lung Cancer Metastatic

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02872116 2025-08-07

CheckMate649

Phase 3 Completed

2,031 enrolled 19 charts 1 FDA

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04026412 2025-07-24

CheckMate73L

Phase 3 Completed

925 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT01844505 2025-05-21

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Phase 3 Completed

945 enrolled 19 charts

Melanoma

NCT02388906 2025-04-24

CheckMate 238

Phase 3 Completed

906 enrolled 16 charts 1 FDA

Melanoma

NCT02017717 2025-04-04

CheckMate 143

Phase 3 Completed

529 enrolled 28 charts

Glioblastoma

NCT03138512 2024-12-18

CheckMate 914

Phase 3 Completed

1,641 enrolled 21 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT04340193 2024-11-26

CheckMate 74W

Phase 3 Completed

26 enrolled 15 charts

Gastrointestinal

Liver Neoplasms

NCT02899299 2024-05-21

CheckMate743

Phase 3 Completed

605 enrolled 17 charts 1 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT02864251 2023-09-28

CheckMate722

Phase 3 Completed

367 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT03302234 2023-09-26

KEYNOTE-598

Phase 3 Completed

568 enrolled 20 charts

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02741570 2023-09-21

CheckMate 651

Phase 3 Completed

947 enrolled 19 charts

Head and Neck Neoplasms

NCT03351361 2023-03-01

eNERGY

Phase 3 Completed

Advanced Non Small Cell Lung Cancer

NCT02538666 2023-01-05

CheckMate 451

Phase 3 Completed

907 enrolled 17 charts

Lung Neoplasms

NCT02714218 2022-06-24

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Phase 3 Completed

387 enrolled 28 charts

Melanoma

NCT03068455 2021-09-20

CheckMate 915

Phase 3 Completed

1,844 enrolled 14 charts

Melanoma

NCT02599402 2021-06-15

CheckMate 401

Phase 3 Completed

533 enrolled 19 charts

Melanoma

NCT02905266 2020-12-17

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

Phase 3 Completed

106 enrolled 20 charts

Melanoma

NCT01450761 2020-07-08

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Phase 3 Completed

1,351 enrolled 10 charts

Small Cell Lung Carcinoma

NCT01285609 2020-06-18

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Phase 3 Completed

1,289 enrolled 14 charts

Lung Cancer - Non Small Cell Squamous

NCT01866319 2020-06-02

MK-3475-006

Phase 3 Completed

834 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02545075 2020-05-19

A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine

Phase 3 Completed

182 enrolled 20 charts

Melanoma

NCT02279732 2019-08-28

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Phase 3 Completed

342 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01515189 2019-07-31

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Phase 3 Completed

831 enrolled 16 charts

Melanoma

NCT00861614 2016-09-30

Study of Immunotherapy to Treat Advanced Prostate Cancer

Phase 3 Completed

988 enrolled 19 charts

Prostatic Neoplasms

NCT01057810 2016-08-18

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Phase 3 Completed

837 enrolled 15 charts

Prostatic Neoplasms

NCT00324155 2014-11-03

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Phase 3 Completed

681 enrolled 24 charts

Melanoma

NCT00094653 2011-07-11

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Phase 3 Completed

1,783 enrolled 29 charts

Melanoma, Neoplasm Metastasis, Skin Neoplasms